The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today approved the proposal of the Executive Board and Supervisory Board, resolving to pay a dividend of EUR 0.22 per share for the 2025 fiscal year, up from EUR 0.17 per share the previous year. The decision underscores the company's robust financial health and commitment to delivering shareholder value. As in prior years, the meeting was held as an in-person event near the Eckert & Ziegler SE headquarters in Berlin, with 55.37% of the company's share capital represented. Shareholders endorsed the actions of the Executive Board and Supervisory Board for the 2025 fiscal year and approved all agenda items by a large majority.
The dividend increase reflects Eckert & Ziegler's strong operating performance and its strategic focus on growth in the radiopharmaceutical and nuclear medicine sectors. The company, a leading specialist for isotope-related components, has benefited from rising demand for diagnostic and therapeutic radiopharmaceuticals. The approved dividend payout signals management's confidence in the company's future cash flows and profitability. Detailed voting results and the CEO's presentation are available on the Eckert & Ziegler SE website at https://www.ezag.com/investors/annual-general-meeting/.
The higher dividend also aligns with broader industry trends, as nuclear medicine continues to gain traction for targeted cancer therapies and imaging. Eckert & Ziegler, with over 1,000 employees, offers a comprehensive range of services from early development to contract manufacturing and distribution. The company's inclusion in the TecDAX index of Deutsche Börse further underscores its significance in the German technology and healthcare landscape. The approval of the dividend and all agenda items by a large majority indicates strong shareholder alignment with the company's strategic direction. As the company continues to expand its capabilities and market reach, the dividend increase serves as a tangible reward for investor confidence.
